Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR2 | P50052 | 2/20 | 0.75 |
| ▸ | PPARG | P37231 | 3/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | AGTR1 | P30556 | 3/20 | 0.44 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.44 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.44 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.44 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.44 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL683375 | 0.95 | AGTR2 (0.67) | AGTR2PPARGKCNH2AGTR1ABCC3 | |
| SCHEMBL684052 | 0.91 | AGTR2 (0.60) | AGTR2PPARGKCNH2AGTR1 | |
| SCHEMBL683705 | 0.90 | AGTR2 (0.62) | AGTR2PPARGKCNH2AGTR1ABCC3 | |
| SCHEMBL682534 | 0.90 | AGTR2 (0.62) | AGTR2PPARGAGTR1ABCC3ABCC4 | |
| SCHEMBL684048 | 0.86 | AGTR2 (0.57) | AGTR2PPARGKCNH2AGTR1 | |
| Azilsartan Medoxomil SCHEMBL683374 | 0.86 | AGTR2 (1.00) | AGTR2PPARGKCNH2AGTR1ABCC3 | |
| Azilsartan Medoxomil SCHEMBL29861385 | 0.86 | AGTR2 (1.00) | AGTR2PPARGKCNH2AGTR1ABCC3 | |
| Azilsartan Medoxomil SCHEMBL967309 | 0.85 | AGTR2 (0.99) | AGTR2PPARGKCNH2AGTR1ABCC3 | |
| Azilsartan Medoxomil SCHEMBL967313 | 0.85 | AGTR2 (0.99) | AGTR2PPARGKCNH2AGTR1ABCC3 | |
| Azilsartan Medoxomil SCHEMBL968583 | 0.85 | AGTR2 (0.99) | AGTR2PPARGKCNH2AGTR1ABCC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110046090-A1 | MODULATION OF NEUROGENESIS WITH GABA AGENTS AND GABA ANALOGS | BRAINCELLS INC. (US) | 2011-02-24 | — | — | US | disclosed |
| US-20110046090-A1 | MODULATION OF NEUROGENESIS WITH GABA AGENTS AND GABA ANALOGS | BRAINCELLS INC. (US) | 2011-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046090-A1 | MODULATION OF NEUROGENESIS WITH GABA AGENTS AND GABA ANALOGS | GAP43, GABRB1, GABRB3 | AGTR2 2610/4885PPARG 156/4885KCNH2 4093/4885 |
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | NGF, DCX, BDNF | AGTR2 9/4885PPARG 622/4885KCNH2 2626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.